News
MyChesCo on MSN43m
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast CancerPositive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback